Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing early transcriptional changes following drug treatment of mutant EGFR-addicted cells, we identified the stem cell transcriptional regulator SOX...

Full description

Bibliographic Details
Main Authors: S Michael Rothenberg, Kyle Concannon, Sarah Cullen, Gaylor Boulay, Alexa B Turke, Anthony C Faber, Elizabeth L Lockerman, Miguel N Rivera, Jeffrey A Engelman, Shyamala Maheswaran, Daniel A Haber
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2015-02-01
Series:eLife
Subjects:
targeted cancer therapy
EGFR mutation
SOX2
resistance
lung cancer
Online Access:https://elifesciences.org/articles/06132

Internet

https://elifesciences.org/articles/06132

Similar Items